Deregulation of SLC30A9 expression was also reported for hepatocellular carcinoma (HCC) (Gartmann et al., 2018) and prostate cancer (PCa) (Singh et al., 2016). This evidence concerns the gene SLC30A9 and posterior cortical atrophy.